13662-60-7

Usage

Uses

Used in Pharmaceutical Industry:
Chalcone serves as a crucial intermediate in the synthesis of various pharmaceutical compounds due to its versatile reactivity. Its potential pharmacological effects, such as antioxidant, anti-inflammatory, anticancer, and antimicrobial activities, make it a promising candidate for the development of new drugs and bioactive molecules.
Used in Chemical Research:
Chalcone's unique structure and reactivity render it an indispensable tool in chemical research. It is utilized in the synthesis of a broad spectrum of natural and synthetic compounds, contributing to the advancement of chemical knowledge and the creation of novel chemical entities.
Used in Antioxidant Applications:
Chalcone is employed as an antioxidant, leveraging its ability to combat oxidative stress and protect cells from damage. This makes it a valuable component in the development of health supplements and therapeutic agents aimed at preventing or treating diseases associated with oxidative stress.
Used in Anti-Inflammatory Applications:
Harnessing its anti-inflammatory properties, chalcone is utilized in the development of agents that can mitigate inflammation. This application is particularly relevant in the treatment of conditions characterized by chronic inflammation, such as arthritis and autoimmune disorders.
Used in Anticancer Applications:
Chalcone is explored for its potential as an anticancer agent, with studies indicating its ability to inhibit the growth and proliferation of cancer cells. It is being investigated for its role in the development of novel therapeutics targeting various types of cancer.
Used in Antimicrobial Applications:
Leveraging its antimicrobial activities, chalcone is employed in the development of agents that can combat microbial infections. This application is significant in the context of increasing antibiotic resistance and the need for new antimicrobial agents.

Upstream product

• 92-52-4 biphenyl 
• 92-91-1 biphenyl-4-acetaldehyde 
• 104-88-1 4-chlorobenzaldehyde 

Downstream Products

• 76288-01-2 3-Biphenyl-4-yl-5-(4-chloro-phenyl)-isoxazole 
• 1017240-34-4 3-Biphenyl-4-yl-5-(4-chloro-phenyl)-4,5-dihydro-1H-pyrazole 
• 76287-97-3 3-Biphenyl-4-yl-5-(4-chloro-phenyl)-4,5-dihydro-isoxazole 
• 1027906-58-6 3-biphenyl-4-yl-5-(4-chloro-phenyl)-cyclohex-2-enone 
• 861406-41-9 C₂₅H₂₂ClN₃O 
• 50497-93-3 4,5-dihydro-1-phenyl-3-diphenyl-5-(4-chlorophenyl)-1H-pyrazole 
• 77153-39-0 (trans)-1-p-biphenylyl-2-(p-chlorophenyl)cyclopropane 
• 77153-38-9 (cis)-1-p-Biphenylyl-2-(p-chlorophenyl)cyclopropane 
• 1027392-50-2 4-biphenyl-4-yl-6-(4-chloro-phenyl)-2-oxo-cyclohex-3-enecarboxylic acid ethyl ester 

Relevant academic research and scientific papers

Synthesis and characterization of 2-phenylpyrazoline derivatives and evaluation of their activities against antimicrobial and breast cancer cell line in vitro and in silico studies

The new series of 2-phenylpyrazoline derivatives (2a-j) were synthesized and evaluated for their antimicrobial, in silico and in vitro anticancer activity was performed by MTT assay using MDA-MB-231 (human breast adenocarcinoma) cell line. The 2-phenylpyr

Design, synthesis, and biological evaluation of polyphenols with 4,6-diphenylpyrimidin-2-amine derivatives for inhibition of Aurora kinase A

Background: Several 4,6-diarylpyrimidin-2-amine derivatives show anticancer properties. However, their mode of action is not fully characterized. To develop potent anticancer chemotherapeutic agents, we designed and synthesized 25 4,6-diphenylpyrimidin-2-amine derivatives containing a guanidine moiety. Methods: Clonogenic long-term survival assays were performed to screen anticancer compounds. To derive the structural conditions showing good cytotoxicities against cancer cells, quantitative structure-activity relationships (QSAR) were calculated. Biological activities were determined by flow cytometry for cell cycle analysis and by immunoblot analysis for the detection of Aurora kinase A (AURKA) activity. Because 2-(2-Amino-6-(2,4-dimethoxyphenyl)pyrimidin-4-yl) phenol (derivative 12) selectively inhibited AURKA activity from the kinome assay, in silico docking experiments were performed to elucidate the molecular binding mode between derivative 12 and AURKA. Results: The pharmacophores were derived based on the QSAR calculations. Derivative 12 inhibited AURKA activity and reduced phosphorylation of AURKA at Thr283 in HCT116 human colon cancer cells. Derivative 12 caused the accumulation of the G2/M phase of the cell cycle and triggered the cleavages of caspase-3, caspase ?7, and poly(ADP-ribose) polymerase. The binding energies of 30 apo-AURKA – derivative 12 complexes obtained from in silico docking ranged from ?16.72 to ?11.63 kcal/mol. Conclusions: Derivative 12 is an AURKA inhibitor, which reduces clonogenicity, arrests the cell cycle at the G2/M phase, and induces caspase-mediated apoptotic cell death in HCT116 human colon cancer cells. In silico docking demonstrated that derivative 12 binds to AURKA well. The structure-activity relationship calculations showed hydrophobic substituents and 1-naphthalenyl group at the R2 position increased the activity. The existence of an H-bond acceptor at C-2 of the R1 position increased the activity, too.

Synthesis and characterization of 2-pyrazoline derivatives and their in silico and in vitro studies on antimicrobial and anticancer activities

The new series of 1-(4,5-dihydro-5-phenyl-3-diphenylpyrazol-1-yl)butan-1-one derivatives were synthesized by cyclization method using biphenyl chalcone with n-butyric acid and hydrazine hydrate. The synthesized 1-(4,5-dihydro-5-phenyl-3-diphenylpyrazol-1-

An efficient synthesis and in vitro antimicrobial screening of 2-cyanoimino-4-aryl-6-(1,1′-biphenyl-4-yl)-3, 4-dihydro-1H-pyrimidines

An efficient synthesis of 2-Cyanoimino-4-aryl-6-(1,1′-biphenyl-4-yl)-3,4-dihydro-1H-pyrimidines from stryl-4-biphenylketones and cyanoguanidine in presence of sodium hydroxide has been described. Cyanoguanidine serves as N-C=N source for the construction of desired cyanoiminopyrimidines. The structural assignments of the titled products were done accordingly to their spectra like Mass, FT-IR, Proton and Carbon-13NMR spectroscopy. The more stable tautomeric form was ascertained using computational frequency analysis. The tested microorganism profile of compounds exhibits significant antimicrobial activity.

SAR studies of differently functionalized 4′-phenylchalcone based compounds as inhibitors of cathepsins B, H and L

Conditions related to the elevated levels of cathepsin B [3.4.22.1], cathepsin H [3.4.22.16] and cathepsin L [3.4.22.15] in various cancerous, rheumatoid arthritis and tissue degenerative disorders motivate the design, synthesis and evaluation of compound

ALLOSTERIC PROTEIN KINASE MODULATORS

The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.

Synthesis and antibacterial activity of some 5-(4-biphenylyl)-7-aryl[3,4-d] [1,2,3]-benzothiadiazoles

A series of 5-(4-biphenylyl)-7-aryl[3,4-d] [1,2,3]-benzothiadiazoles were synthesized, characterized by IR, NMR and elemental analysis and evaluated for in vitro antibacterial activity against some Gram-positive and Gram-negative bacteria. The antibacterial data revealed that compounds 7a-j had better activity against tested Gram-positive organisms than the reference ciprofloxacin and norfloxacin. However, the compounds were nearly inactive against Gram-negative bacteria. Compound 7c and 7d were the most active compounds against Gram-positive bacteria.

Synthesis and antibacterial activities of some 2-amino-4,6- diarylpyrimidines

A series of 2-aminopyrimidines have been prepared by the condensation of 1-(1,1′-biphenyl-4-yl)-3-arylprop-2-en-1-ones with guanidine-nitrate and characterized on the basis of analytical and spectral data. The compounds have been screened for their antibacterial activities.

Substituent effects on 1H and 13C NMR chemical shifts in styryl fluorenyl and styryl biphenyl ketones

Several substituted styryl 2-fluorenyl ketones and styryl 4-biphenyl ketones have been prepared and their 1H and 13C NMR spectra recorded. While the chemical shifts of β-protons and β-carbons in styryl 2-fluorenyl ketones exhibit goo

Kinetic Study of the Homolytic Brominolysis of 1,2-Diarylcyclopropanes

The rate constants for the photolytic brominolysis of 22 trans-1,2-diarylcyclopropanes in carbon disulfide relative to an internal standard, p-chlorotoluene, have been determined.The products of the brominolysis are 1,3-dibromo-1,3-diarylpropanes.The rate constants range over 5 orders of magnitude, being enhanced by electrondonating substituents on one or both benzene rings.The quantitative size of the substituent effect (ρ) at either involved carbon center is a function of the substituent at the other center.This fact suggests a continuum of transition-state structures with varying degrees of bond breaking and charge separation.